HeartBeam to Discuss Q2 Results and Strategy for Accelerating Global Adoption of Ambulatory ECG Platform
Found this article helpful?
Share it with your network and spread the knowledge!
HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care, announced it will host a conference call on Aug. 13 at 4:30 p.m. ET to discuss financial results for the second quarter ended June 30, 2026, and provide updates on its strategy to accelerate global adoption of its ambulatory ECG signal platform. The call will be led by Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, and Chief Financial Officer Timothy Cruickshank, and will include a question-and-answer session following prepared remarks.
The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management.
HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to technology enablement. The cleared indications for use are available at HeartBeam's indications page.
For investors and the healthcare industry, this call provides insight into the company's progress in commercializing a technology that could significantly reduce the cost and complexity of cardiac monitoring. By enabling high-quality ECG data collection outside clinical settings, HeartBeam's platform has the potential to expand access to cardiac diagnostics, improve early detection of arrhythmias, and reduce hospital readmissions. The company's strategy to accelerate global adoption will be critical to capturing a share of the growing ambulatory cardiac monitoring market, which is driven by an aging population and increasing prevalence of heart disease.
The full press release can be viewed at this link. Additional news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.